Semaglutide linked to fewer limb problems in people with type 2 diabetes and artery disease or foot ulcers

In a study of 334 participants with type 2 diabetes, the incidence of major limb events was 43.0% in the semaglutide group compared to 56.0% in those using other glucose-lowering therapies.

• Major limb events, including critical limb ischaemia and peripheral angioplasty, occurred at a rate of 8.1 events per 100 person-years in the semaglutide group.
• The semaglutide group had a significantly lower hazard ratio of 0.77 for major limb events compared to the other glucose-lowering therapies.
• Lower extremity amputation rates were 50% lower in the semaglutide group, with a hazard ratio of 0.50.
• The study included participants with peripheral artery disease or foot ulcers, predominantly males aged 61 years.
• Participants had a median follow-up of 30.1 months, with a baseline HbA1c of 8.0% and a body mass index of 31 kg/m.

Simplified